Acceptable Hemodynamic Changes in Dexmedetomidine for Single Intravenous Bolus Injection
Status:
Unknown status
Trial end date:
2020-04-23
Target enrollment:
Participant gender:
Summary
Dexmedetomidine（DEX）is a potent and highly selective α 2 adrenergic receptor agonist. It has
the pharmacological effects of sedation, hypnosis, analgesia, anti-sympathetic and
neuroprotective. Its sedative effect is similar to normal sleep, and easy to wake up. DEX is
widely used clinically because of its advantages and acceptable side effects. The best
clinical use of DEX is uncertain, including intravenous, intramuscular, oral, intralnasal and
sublingual administration. Its clinical recommended use is intravenous load infusion for more
than 10 minutes, followed by continuous infusion. However, the clinical recommended usage is
inconvenient, time-consuming and other shortcomings, for the growing popularity of daytime
surgery, will inevitably affect the operation process and turnover. If a suitable dose range
of DEX can be found for a single intravenous injection to achieve clinical efficacy quickly
without significant hemodynamic effects, this will improve the patient's postoperative
recovery. We will speed up the utilization and turnover of medical resources. The aim of this
study was to investigate the optimal dosage of DEX for single intravenous injection.
Phase:
Phase 4
Details
Lead Sponsor:
Second Affiliated Hospital of Wenzhou Medical University